Mar 22, 2016
The incidence of melanoma, the most deadly form of skin cancer, has doubled in the past 40 years. Globally, in 2012, melanoma occurred in 232,000 people and resulted in 55,000 deaths. In 2016, it is estimated that there will be 76,380 new cases of melanoma in the United States and 10,130 deaths from the disease. If melanoma is diagnosed and treated early, it is typically curable, but if it is not, melanoma becomes hard to treat and is often fatal.
In a study published in the Dermatology Surgery Journal, a 19 min MART-1 immunostaining protocol using BioGenex pretreatment reagents, MART-1 Antibody and BioGenex Super Sensitive Link-Label detection system, was developed (Read full manuscript). The nineteen min immunostaining protocol in frozen sections provided information equivalent to that obtained from MART-1 stained permanent sections. The rapid turnaround time of the 19-minute protocol allows melanoma in situ to be treated using Mohs surgery within a matter of hours as opposed to days or weeks. This protocol allows increasing the number of layers that can be taken in a single day and processed using immunohistochemistry. This increase in efficiency ultimately improves the experience for the patient.
In a new study publish in the Journal of the American Academy of Dermatology, researchers have now proven that combining Mohs surgery with MART-1 immunostaining is a very effective strategy achieving a very low recurrence rates for in situ and invasive melanomas. To read the full study please check the link.
Mohs surgery is a precise surgical technique used to treat skin cancer. During Mohs surgery, thin layers of cancer-containing skin are progressively removed and examined until only cancer-free tissue remains. It can be difficult to identify melanocytes and to distinguish chronic sun-damaged skin from melanoma using hematoxylin and eosin (H&E)-stained frozen sections. This difficulty led to the use of MART-1 immunostaining. MART-1 (also called melan-A) is a protein antigen that is specifically found on the surface of normal melanocytes in the skin and in melanoma. MART-1 staining using permanent sections can take days, thus reducing the efficiency and cost-effectiveness of this procedure.
The 19-min MART-1 immunostaining protocol used BioGenex Citra Buffer (HK080-9K), BioGenex Super Sensitive MultiLink (HK340-9K) and BioGenex Super Sensitive Label (HK330-9K). Mart-1 (Melan-A) Antibody for manual or automation use and positive control tissue slides are available from BioGenex as follows: AM361-5M (6 ml, RTU), MU361-UC (1 ml Conc.), MU361-5UC (0.5 ml, Conc.), AM361-10M (i6000, 10 ml, RTU), AX361-YCD (Xmatrx, 16 ml, RTU), FG-361M (5 tissue slides/Manual use), FB-361M (5 tissue slides/Xmatrx).
Click on Antibody Page to find more.
BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.